Skip to main content
OpenTrials
Completed

NCT Number: NCT00209768

Use of In-Line Filtration in Critically Ill Children

The purpose of this study is to determine whether the use of in-line filtration shows any effect on the outcome of sepsis, systemic inflammatory response syndrome (SIRS), thrombosis, or organ failure in critically ill children admitted to the pediatric intensive care unit (PICU).

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hannover Medical School

Hanover, Lower Saxony, 30625, Germany

About this study

Scientific background:

Particulate contamination of infusion solutions and their systemic administration during infusion therapy has been linked to various clinical problems.

Organ failure and Multi-Organ Failure (MOV):

It is well established that the pathophysiology of MOV involves deteriorations of the microcirculation and integrity of endothelial cells. As a consequence of this an imbalance between pro- and anticoagulatory factors may develop and microthrombi may form. Mediators like tissue factor (TF) and platelet activating factor (PAF) have been linked to the formation of microthrombi.

Particles have been discussed as a causative agent for this syndrome by various authors. Their effect on morbidity and mortality of patients has however not yet been established.

Particles may have additional harmful effects:

  • Direct thrombogenesis by the particle material
  • Damaging endothelial cells in the capillary network
  • Embolisation of the pulmonary vasculature
  • Acting as a cristallisation focus for the development of granuloma
  • Promoting the formation of Giant Cells

Various authors have shown that the use of end line infusion filters significantly reduces the rate of thrombophlebitis. A recently published study by van Lingen et al. (2004) also showed that the use of end line infusion filters significantly reduced the rate of overall complications in neonates.

Study Hypothesis:

The use of end line positively charged 0.2 µm and uncharged 1.2 µm infusion filters will prevent particles, microorganisms and their endotoxins from the infusate to enter the patient's circulation in the study group and will reduce significantly the complication rate of these patients.

The following clinical diagnoses are defined as "Complications". They are main contributors to morbidity and mortality in intensive care wards:

  • catheter related thrombosis of the central veins
  • sepsis with proven infectious organisms
  • Septic syndrome without proven infectious organisms
  • Failure of one of the following organs/systems
  • Lung
  • Kidney
  • Liver
  • Circulation

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children admitted to pediatric intensive care unit (PICU)

Exclusion criteria

  • Suspected death within 48 hours
  • Duration of PICU stay less than 6 hours
  • Patients recruited for Simulect or Sintra Study

Treatment and study plan

Filter: NOE96E, ELD96E, NLF1E, TNA1E

Device

Primary outcomes

  1. Sepsis

  2. Thrombosis

  3. SIRS

  4. Organ failure

  5. Composite primary outcome including "sepsis, SIRS, thrombosis, organ failure"

Secondary outcomes

  1. Duration of Pediatric Intensive Care Unit stay

  2. Duration of overall hospital stay

Sponsors and collaborators

Lead sponsor

Hannover Medical School

Other

Collaborators

  • B. Braun Melsungen AG
  • Pall Corporation

Registry information

Official study title

Randomised, Prospective Study of the Use of In-Line Filtration on the Reduction of Complication Rate in Critically Ill Children

Important dates

Study start
2005
Primary completion
2008
Study completion
2008
First posted
Sep 21, 2005
Registry last updated
Dec 1, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.